Tillman Gerngross steers a biotech unicorn to Nasdaq, while another company's IPO plans fizzle
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
The biotech industry was set to end this week with another two major public debuts. The first company, Tillman Gerngross’ antibody startup Adagio Therapeutics, priced a $300 million-plus IPO on Thursday, bringing its valuation to around $2 billion. But the second, WCG Clinical, fell through on its IPO plans, missing out on a potential $720 million raise.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.